Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT06512350 | Identifying Patterns in the Breath of Individuals With Breast Cancer | recruiting | — | 5,175 | Breathe BioMedical IncINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula |
| terminated |
| N/A |
| 7 |
| GenieBiome LimitedINDUSTRY |
| 1 |
| Sep 18, 2026 |
| clinicaltrials |
| NCT06746688 | A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. | active not recruiting | Phase 1 | 40 | ExpreS2ion BiotechnologiesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06846060 | A Mindfulness-Based Self-Compassion Program | completed | N/A | 64 | Nevsehir Haci Bektas Veli UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06882499 | Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II(AVATARII) | not yet recruiting | N/A | 74 | Peter MacCallum Cancer Centre, AustraliaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies(EVOLVE-BDT) | recruiting | Phase 2 | 700 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07487844 | Pulsed Electric Field Ablation for Metastatic Breast Cancer | recruiting | N/A | 20 | University of California, San FranciscoOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07631026 | Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery | not yet recruiting | N/A | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07676383 | Precision Navigation to Improve Community Cancer Screening Participation | recruiting | N/A | 1,500 | Hunan Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07679269 | Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.(EPIK-RO) | not yet recruiting | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828054 | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan(MARGARET) | not yet recruiting | Phase 3 | 244 | Mario Negri Institute for Pharmacological ResearchOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) | not yet recruiting | — | 2,000 | Yeon Hee ParkOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828925 | Selective Axillary Dissection After Neoadjuvant Chemotherap Yin Patients With Lymphnode-positive Breast Cancer(CLYP) | completed | — | 105 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT00417495 | Sentinel Lymph Node Technique in Multifocal Breast Cancer(IGASSU) | completed | Phase 2 | 216 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00904410 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET(CHIMTEP) | completed | Phase 4 | 63 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00911911 | Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy(SPAM) | completed | N/A | 66 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01613482 | TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention(TSARINE) | terminated | Phase 3 | 13 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01658462 | Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer(VAROCE) | completed | Phase 2 | 51 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02281149 | Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy:(TOMOBREAST) | completed | — | 500 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04653740 | Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer(OMERIC) | active not recruiting | N/A | 25 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04889924 | ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer(ADARNAT) | recruiting | N/A | 820 | Hospital Universitari de BellvitgeOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT05763641 | TAD After Chemotherapy in Locally Advanced Breast Cancer | recruiting | — | 162 | Hospital Universitari de BellvitgeOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05782686 | Impact of Systematic Shaving on Margins | recruiting | N/A | 234 | Hospital Universitari de BellvitgeOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06339658 | ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy | recruiting | — | 43 | Hospital Universitari de BellvitgeOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06362616 | Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer(PAPBI-3) | recruiting | N/A | 31 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06916637 | Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer | recruiting | — | 40 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | recruiting | Phase 3 | 558 | BioNTech SEINDUSTRY | 17 | Sep 17, 2026 | clinicaltrials |
| NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | recruiting | Phase 1 | 30 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07505797 | ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health(AUDIBLE) | recruiting | — | 800 | iSono Health, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | recruiting | Phase 2 | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07799909 | Behavioral Activation for Cancer-Related Fatigue After Breast Cancer Surgery | completed | N/A | 114 | Huaidong ChengOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07819045 | Self-Acceptance and Supportive Accountability for Active Living Among Adults Receiving Chemotherapy | completed | N/A | 42 | University of OklahomaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824869 | A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 2 | 90 | Shanghai Henlius BiotechINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07825454 | Pilot Study of Hydroxychloroquine for the Treatment of AIMSS(AIMSS) | not yet recruiting | Phase 2 | 35 | Indiana UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826052 | Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer(ELDER) | not yet recruiting | Phase 2 | 494 | Fudan UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07826338 | Artificial Intelligence-supported Mobile Application for Patients With Breast Cancer | recruiting | N/A | 70 | Ege UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02194387 | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | active not recruiting | N/A | 337 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02324387 | Tc99m Sestamibi Molecular Breast Imaging | active not recruiting | N/A | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02926729 | Real-Time Assessment Of Breast Cancer Surgical Specimen Margins With Nonlinear Microscopy | terminated | N/A | 56 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | active not recruiting | Phase 2 | 51 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03667612 | Endogenous Mechanisms of Inactivation of the Endothelium Tumor(BreastIls) | completed | — | 70 | Centre Oscar LambretOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05142787 | Magseed Pro(R)/ Sentimag(R) Gen3 | recruiting | N/A | 224 | Endomagnetics Ltd.INDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials